サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179953

DNA検査の世界市場-2023-2030

Global DNA Testing Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
DNA検査の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

DNA検査の世界市場規模は、予測期間（2023-2030年）にCAGR7.4％で成長するとされています。

DNA検査は、しばしば遺伝子検査として知られ、ヒトの遺伝子、染色体、またはタンパク質の変化を発見することができる医療検査です。これらの変異は、人が遺伝性疾患を患っているか否かを明らかにすることができます。DNA検査は、特定の病気に罹患するリスクや、遺伝的な問題を引き継ぐリスクも決定することができます。DNAの検査は任意です。検査には利点があり、欠点やリスクがあるため、検査を受けるかどうかは、複雑で個人的なものです。遺伝学者や遺伝カウンセラーは、検査の長所と短所を概説し、社会的・感情的な影響を調べることで支援することができます。

市場力学

DNA検査の世界市場を促進する主な要因は、新しい検査と技術的なブレークスルーの開発、消費者向け直接DNA検査の需要の拡大、遺伝性疾患と慢性疾患の頻度の増加が遺伝子検査の世界市場を推進する主な要因です。

新しい検査の開発と技術的ブレークスルーが市場成長の原動力となることが期待されます。

現在、技術開発が加速していることにより、市場成長の機会が広く開かれています。専門的な治療分野の検査キット市場の増加や、慢性疾患の急速な市場拡大を後押ししています。いくつかの国の政府は、遺伝子検査の規制をより重視し、国民の意識を高めることで、遺伝子検査の世界の受け入れの加速化に成功しました。研究開発資金の増強と大手企業の大きな市場プレゼンスにより、新規参入者の高い参入障壁が形成されました。市場で競争力を維持するためには、製品設計の革新、品質基準の向上、強力な販売提携が必要です。

例えば、2022年7月、遺伝性がん遺伝子スクリーニング（GCC）や薬理遺伝学スクリーニング（PGx）など、アポロの専門性の高い高性能NGS検査をより広い臨床市場に提供するため、業界トップのソフトウェア企業である1health.io Inc（以下、1health）はアポロヘルスグループと提携しています。1healthは、診断ラボが臨床市場と消費者直販市場の両方において、迅速かつ安全に検査を拡大できるように支援します。

2022年11月29日、ペーチ大学（UP）とBGI Genomicsは、ハンガリーで共同ラボを開設することを決定しました。これは、同大学とBGI Genomicsの親組織であるBGIグループとの間の協力協定に規定されたものです。

高価なコストが市場成長の妨げになると予想されます。

実験設備は定期的なメンテナンスが必要であり、多額の費用がかかるため、市場拡大を阻む要因の一つとなっています。

COVID-19の影響分析

COVID-19は、市場にも悪影響を及ぼしています。例えば、WHOがCOVID-19をパンデミックと認定した後、社会的隔離に従うロックダウンが世界的に行われたことは、DNA検査市場に悪影響を与えています。遺伝カウンセラーは一般的に患者と1対1で会うことができず、医師はカウンセリングを受けられないことが多く、検査機関も必要な検査ができないことがその原因です。遺伝カウンセラーは、医療サービスセンターのような組織では医療従事者とはみなされません。したがって、彼らはロックダウン中の診療を免除されることはないです。さらに、クリニックでは、病気の封じ込めを支援するために、対面での遺伝カウンセリングを制限していました。

しかし、GeneDx社のような遺伝子検査を提供する会社では、臨床医の要求に応じて遺伝子検査を行うという選択肢を提供しています。病院や他のヘルスケア施設が遠隔医療を利用して遺伝カウンセリングを行うのと同様に、クリニックも同様のことを始めています。さらに、親による検査は、その重要性から、DNA検査の中で最も影響の少ない方法として続いています。

その結果、COVID-19は遺伝子検査の市場に大きな影響を与えています。しかし、現在、遺伝子検査の需要は世界的に流行前の水準に近づいており、このニーズは今後も増加すると予想されます。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 新しい検査の開発と技術的なブレークスルー
      • 消費者直販のDNA検査の需要拡大
    • 抑制要因
      • 高価なコストが市場成長の妨げになると予想されます。
    • 機会（Opportunity
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品タイプ別

  • 器具
  • 試薬
  • ソフトウェア＆サービス

第8章 技術別

  • PCR
  • インサイチュハイブリダイゼーション
  • シーケンサー技術
  • 質量分析
  • その他

第9章 アプリケーション別

  • オンコロジー
  • 感染症検査
  • 筋原性疾患診断
  • 臨床診断確認
  • 出生前診断
  • 着床前診断
  • その他

第10章 エンドユーザー別

  • ポイントオブケア
  • 診断センター
  • セルフテスト/OTC

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Natera, Inc
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Roche Diagnostics
  • Abbott Laboratories
  • Cephide Inc
  • Gen-probe Inc
  • Illumina, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Hologic Inc
  • Siemens Healthier.

第14章 DNA検査の世界市場-DataM

目次
Product Code: DMCD1818

Market Overview

The global DNA testing market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 7.4% during the forecast period (2023-2030).

A DNA test, often known as genetic testing, is a medical examination that can spot changes in human genes, chromosomes, or proteins. These mutations can reveal if a person has a genetic disorder or not. DNA tests can also determine a person's risk of contracting a certain illness or passing along a genetic problem. Testing for DNA is optional. Whether to be tested is complex and personal because there are advantages to testing and drawbacks and risks. A geneticist or genetic counselor can assist by outlining the advantages and disadvantages of the test and by going over its social and emotional implications.

Market Dynamics

The major factors driving the global DNA testing market are the development of new tests and technological breakthroughs, demand for direct-to-consumer DNA testing is expanding. and the growing frequency of genetic and chronic diseases is the primary driver propelling the global market for genetic testing.

The development of new tests and technological breakthroughs is expected to drive the market's growth.

The current acceleration of technical development has opened up a wide range of opportunities for market growth. The increase helps the market for specialist testing kits for specialized treatment sectors and the rapid market expansion of chronic diseases. Governments in several countries have successfully accelerated the global acceptance of genetic testing by putting more emphasis on regulating it and increasing public awareness of it. A high entry barrier for new entrants has been created by the increased R&D funding and the large market presence of major enterprises. Innovation in product design, higher quality standards, and strong distribution alliances are all necessary to keep a competitive edge in the market.

For instance, in July 2022, to bring Apollo's specialized high performing NGS tests, such as hereditary cancer genetic screenings (GCC) and pharmacogenetics screenings (PGx), to the wider clinical market, 1health.io Inc. ("1health"), an industry-leading software company, partners with Apollo Health Group. 1health empowers diagnostic laboratories to expand their testing in both the clinical and the direct-to-consumer markets rapidly and securely.

On November 29, 2022, The University of Pecs (UP) and BGI Genomics decided to open a collaborative lab in Hungary. This is a provision of the cooperation agreement between the University and BGI Group, the parent organization of BGI Genomics.

Expensive cost is expected to hamper the market's growth.

The laboratory equipment needs routine maintenance, which costs a lot of money and is one of the factors limiting market expansion.

COVID-19 Impact Analysis

COVID-19 has also had a detrimental impact on the market. For instance, the global use of lockdowns to follow social segregation to contain COVID-19 after the WHO labeled it a pandemic has negatively impacted the DNA testing market. Genetic counselors are generally unable to meet with patients one-on-one, doctors are often unavailable for counseling, and laboratories cannot do the necessary tests, which is the cause of this. Genetic counselors are not considered healthcare professionals by organizations like the Centres for Medical Services. Therefore they are not exempt from practicing during a lockdown. Additionally, clinics limited in-person genetic counseling to aid in the disease's containment.

However, companies that offer genetic testing, like GeneDx, offer a choice where they give the genetic tests as required by the clinician. Similar to how hospitals and other healthcare facilities use telehealth to offer genetic counseling, clinics are starting to do the same. Additionally, because of its importance, parental testing continues to be the least impacted method of DNA testing.

Consequently, COVID-19 has greatly impacted the market for genetic testing. However, the demand for genetic tests has currently approached pre-pandemic levels globally, and it is anticipated that this need will continue to increase.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The application segment is the highest market holder in the global DNA Testing market. Genetic testing uses medical tests to check for specific gene variants (changes). Several different genetic tests are being used today, and more are being created. There are numerous applications for genetic testing, but this article will concentrate on how it is used to find gene mutations connected to cancer. Predictive genetic testing is used to look for inherited gene alterations that may increase a person's chance of developing particular types of cancer. People with a history of cancer or a particular pattern of cancer in their family may benefit from genetic counseling and testing.

During the projected period, the primary drivers of the cancer segment are the rising incidence of cancers worldwide and the rising public awareness of preventive diagnostics and individualized medication. The American Cancer Society predicted that in 2021 there would be roughly 1,898,160 new cancer cases and 608,570 cancer deaths in the country. The International Agency for Research on Cancer also predicted that by 2040, there would be 30.2 million additional cases of cancer (IARC). Consequently, it is anticipated that an increase in cancer incidence will considerably contribute to the segment's growth.

Genetic tests help determine whether cancer runs in the family and the risk factors for cancer development in the future for people with a family history of the disease. Additionally, genetic testing is done on individuals who do not react to chemotherapy to determine if tumors resistant to treatment have acquired mutations.

Geographical Analysis

Asia Pacific holds the largest market share in the global DNA testing market.

Asia Pacific dominates the global DNA testing market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to the rising frequency of chronic and genetic conditions in the region and the rising demand for individualized genetic testing services, Asia Pacific now dominates the global market for genetic testing. The market expansion in the Asia Pacific is predicted to be driven by the rising number of product approvals by governments and subsequent launches, as well as the high concentration of key players engaged in research activities to innovate novel genetic testing products.

In August 2022, the debut of GENEe- TO The GENE, THE CORRECT WAY, a cutting-edge idea for providing Genetic Counselling services to patients, has been eagerly anticipated by Redcliffe Labs. Additionally, customers can use the recently opened, cutting-edge Genetic Lab in India, the country's first of its type. Redcliffe Labs hopes to provide a complete solution ranging from routine pathology at the basic level to clinical and high-end research genomics with the opening of a specialist Genetics Lab.

In May 2020, A new step of their collaboration with Illumina was announced by the Chinese company Burning Rock, a leader in next-generation sequencing (NGS) oncology diagnosis. In accordance with the new contract, Burning Rock will be the first genetic testing business in China to create in vitro diagnostic (IVD) tests using tissue samples and circulating tumor DNA (ctDNA) on Illumina's NextSeq 550Dx Sequencing System. The cooperation expands on a 2015 partnership that enabled the use of the MiSeq Dx Sequencing System for several NGS-based cancer therapy selection solutions.

Competitive Landscape

The DNA testing market is moderately competitive with local and global companies' presence. Natera, Inc, Roche Diagnostics, Abbott Laboratories, Cephide Inc, Gen-probe Inc, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Hologic Inc, Siemens Healthier and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in October 2022, Medline announced its multi-year vendor partnership with Hoag Memorial Hospital Presbyterian health system to provide essential medical supplies portfolio to the acute and non-acute care network.

Natera, Inc.

Overview: Cell-free DNA (cfDNA) testing pioneer Natera is committed to oncology, women's health, and organ health. In order to safeguard health and enable earlier and more precise actions that result in longer, healthier lives, the goal is to integrate customized genetic testing and diagnostics into the accepted standard of care.

Product Portfolio:

Panorama: Panorama is a blood-based genetic, prenatal screening test of the pregnant person that screens for common chromosomal conditions that affect a baby's health. Panorama uses SNP-based technology to deliver highly accurate results and unique insights for both singleton and twin pregnancies.

The global DNA testing market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The development of new tests and technological breakthroughs
      • 4.1.1.2. Demand for direct-to-consumer DNA testing is expanding.
    • 4.1.2. Restraints:
      • 4.1.2.1. Expensive cost is expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Reagents
  • 7.4. Software & Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. PCR
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. In situ hybridization
  • 8.4. Sequencing Technology
  • 8.5. Mass Spectrometry
  • 8.6. Others

9. By Applications

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 9.1.2. Market Attractiveness Index, By Applications
  • 9.2. Oncology
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious disease testing
  • 9.4. Myogenic disorder diagnosis
  • 9.5. Clinical diagnosis confirmation
  • 9.6. Prenatal diagnosis
  • 9.7. Pre-implantation diagnosis
  • 9.8. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Point of Care
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Self Testing/OTC

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByApplication
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Italy
      • 11.3.8.5. Spain
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. Australia
      • 11.5.8.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Natera, Inc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Roche Diagnostics
  • 13.3. Abbott Laboratories
  • 13.4. Cephide Inc
  • 13.5. Gen-probe Inc
  • 13.6. Illumina, Inc.
  • 13.7. Thermo Fisher Scientific
  • 13.8. Bio-Rad Laboratories
  • 13.9. Hologic Inc
  • 13.10. Siemens Healthier.

LIST NOT EXHAUSTIVE

14. Global DNA Testing Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us